Opinion|Videos|August 7, 2024
Starting CML Treatment: Collaborative Choices for Better Outcomes
Focusing on the initiation of treatment for newly diagnosed patients with CML, Jorge E. Cortes, MD, details important factors to consider when starting treatment and Claire Saxton discusses strategies that optimize communication when considering treatment options.
Advertisement
Episodes in this series
This program was made possible with support from Novartis Pharmaceuticals.
Video content above is prompted by the following questions:
- What are some of the most important considerations when starting treatment for a newly diagnosed patient with CML? How do age, comorbidities, and other considerations factor into the treatment plan?
- Describe your best practices in helping newly diagnosed patients with CML better understand their treatment plan given the complexities involved.
- In your experience, what strategies promote transparent communication around treatment considerations?
- How can patients feel empowered to collaborate with their healthcare team to make an informed decision on the optimal initial treatment?
Advertisement
Related to this article
In the phase 2 EVITA trial, vitamin C did not slow clonal growth but was linked to fewer serious adverse events and longer exploratory survival.
FDA approves pirtobrutinib for untreated CLL/SLL without 17p deletion based on BRUIN CLL-313 data. Read key nursing safety takeaways.
Most oral blood cancer drug prescriptions were first rejected by insurers, and fill rates fell sharply when out-of-pocket costs topped $175.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Sunvozertinib Now Available in US for Pretreated EGFR Exon 20+ NSCLC
2
Male Breast Cancer: Managing Endocrine Therapy and Survivorship Care
3
What Oncology Nurses Need to Know About ADCs in Breast Cancer
4
FDA Grants Traditional Approval to Pembrolizumab in TMB-H Solid Tumors
5